Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

NCT01355302 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01355302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01355302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2011
Completion date
July 31, 2013
Enrollment
7 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, previously untreated gastric cancer